Clinical utility of the Platelet-to-neutrophil ratio in differentiating sepsis from neonatal pneumonia: an observational study
Abstract
Abstract Background In some cases, neonates with pneumonia can develop sepsis. The timely and accurate diagnosis of sepsis due to neonatal pneumonia poses a challenge for many clinicians. Therefore, this study aimed to evaluate the potential of the platelet-to-neutrophil ratio (PNR), as an early biomarker for clinically differentiating neonatal sepsis among pneumonia cases. Methods We performed a cross-sectional analysis of clinical and laboratory data collected from 1,103 patients with neonatal pneumonia [773 with pneumonia and 330 with pneumonia and sepsis (PS)]. Results The PS group had a lower PNR than the pneumonia group. Further analysis revealed that the incidence of PS was significantly higher in the low PNR group than in the high PNR group (43.9% vs. 15.9%, p < 0.01). Multivariate logistic regression analysis revealed that the PNR was an independent risk factor for sepsis in neonatal pneumonia. Receiver operating characteristic curve analysis demonstrated that the PNR has good efficacy in diagnosing neonatal patients with PS (area under curve = 0.76, 95% confidence interval: 0.73–0.80, p < 0.001). Conclusions PNR can serve as an early biomarker for differentiating neonatal sepsis among pneumonia cases. Despite its potential, the PNR requires validation in multicenter studies.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 1,103 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.